WeVote
Log In

Bill

Bill

HR 9149

To establish the National Diabetes Project, and for other purposes.

119th Congress Introduced by John James

The bill would create a National Diabetes Project to coordinate federal efforts across agencies to prevent, treat, and research diabetes and reduce disparities.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 9149

Overview

HR 9149, introduced in the 119th Congress and referred to the House Committee on Energy and Commerce, seeks to establish the National Diabetes Project and related measures. The bill has a co-sponsor (John James). As of the provided action history, the bill has been introduced and referred to committee.

Purpose and intent

  • Create a centralized nationwide initiative—the National Diabetes Project—with the goal of reducing the prevalence and burden of diabetes in the United States.
  • Coordinate federal efforts across agencies to accelerate prevention, detection, treatment, and research related to diabetes.
  • Improve outcomes for individuals with diabetes and at-risk populations through comprehensive programmatic and policy actions.

Key provisions and changes (as described by title and typical framework for such legislation)

  • Establishment of the National Diabetes Project:
    • Likely designates a lead office or interagency working group to oversee diabetes-related activities across federal agencies.
    • Defines missions, goals, and performance measures to track progress in prevention, management, and research.
  • Interagency coordination:
    • Creates formal mechanisms for collaboration among relevant agencies (e.g., Department of Health and Human Services, CDC, NIH, and other public health or social service entities).
    • Enables data sharing, aligned Federal strategies, and joint funding opportunities to maximize impact.
  • Funding and resources:
    • Authorizes appropriations or establishes a funding stream to support the Project’s programs, including prevention, treatment access, and research initiatives.
    • May set annual reporting or requirement for budget planning to Congress.
  • Research and innovation:
    • Promotes diabetes research acceleration, including translational research, clinical trials, and innovative care delivery models.
    • Encourages public-private partnerships, grants, and pilot programs to test new interventions.
  • Prevention and public health:
    • Implements or expands national prevention strategies aimed at reducing risk factors (e.g., obesity, physical inactivity, unhealthy diets).
    • Supports screening, early detection, and cost-effective management to prevent complications.
  • Equity and access:
    • Addresses disparities in diabetes incidence, treatment, and outcomes among racial, ethnic, rural, low-income, and other underserved populations.
    • May include targeted outreach, culturally competent care initiatives, and access to affordable medications and supplies.
  • Accountability and reporting:
    • Requires periodic reporting to Congress on metrics, outcomes, and program effectiveness.
    • Establishes accountability mechanisms for project leadership and participating agencies.

Who is affected

  • Individuals with diabetes and those at risk of developing diabetes, through improved prevention, treatment access, and care coordination.
  • States, localities, healthcare providers, and public health departments that interact with federal diabetes initiatives.
  • Researchers and institutions receiving federal research funding or participating in interagency projects.
  • Federal agencies involved in health, education, and social services that collaborate under the Project.

Procedural and timeline aspects

  • Introduction and referral:
    • Introduced in the House and referred to the Committee on Energy and Commerce for consideration.
  • Potential committee actions:
    • The committee may markup, amend, and vote on the bill, followed by potential passage to the full House.
  • Implementation timeline:
    • If enacted, the Project would require rulemaking, funding allocations, interagency agreements, and phased program rollouts, with progress assessed through annual or periodic reports to Congress.

Notes

  • The summary reflects the bill’s stated name and presumed framework for a national diabetes initiative. Specific statutory text would detail exact authorities, governance structure, funding levels, reporting requirements, and any sunset or renewal provisions.

If you’d like, I can tailor this summary to include any available committee language, funding amounts, or timelines once the bill’s full text is released.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.